NanoEnTek has key technology of nano scale Bio-MEMS that organizationally combined microelectromechanical system(MEMS) and biotechnology called technology of 21st century. Based on the technology, we are expanding business to life science experiment equipment, medical in-vitro diagnostic device, and related solution development. There are about 100 patents of nano convergence technology that were applied and registered. Especially, one of our company’s key platforms is lab-on-a-chip, and it is a next generation technology that will contribute in medicine and life science areas.
NanoEnTek released the world’s first compact automatic cell analyzer named Countess. In 2009, we sold patent and patent exclusive license of gene delivery system MicroPorator to a global company in (US 13M$). We will push forward global target by the world’s first bench-top residual white blood cell counter ADAM-rWBC, point of care diagnostic devices FREND™ PSA Plus, and FREND™ TSH FDA 510(k) cleared in the United States.
Through active investment, NanoEnTek is now expanding in-vitro diagnostic business with existing life science business. In January 2016, we merge with Bio Focus which is a point of care diagnostic devices company based on rapid kit. We have reinforced biology capability and present customized products for each country because of diversification in platform. Until 2020, NanoEnTek will develop as a global leader in point of care diagnostic device area through advanced and various area like immunoassay, blood cell count, companion diagnostics, clinical chemistry, and so on.